8-K: Salarius Pharma Announces 1-for-15 Reverse Stock Split

Salarius Pharmaceuticals will effect a 1-for-15 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement.

Summary

• Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) announced a 1-for-15 reverse stock split.
• The split will be effective at 5:00 p.m. Eastern Time on August 15, 2025.
• Beginning with the opening of trading on August 18, 2025, Salarius common stock will trade on the Nasdaq Capital Market on a split-adjusted basis under a new CUSIP number 79400X503.
• The primary purpose of the reverse stock split is to enable Salarius to regain compliance with the $1.00 minimum closing bid price required for continued listing on the Nasdaq Capital Market.
• At a special meeting of stockholders held on July 8, 2025, stockholders approved the proposal to authorize the Board of Directors to effect a reverse split at a ratio ranging from 1-for-4 to 1-for-40.
• The specific 1-for-15 ratio was subsequently approved by the Board of Directors.
• The number of shares of common stock issued and outstanding will be reduced from approximately 7.6 million shares to approximately 509,000 shares.
• All outstanding options and warrants entitling their holders to purchase shares of common stock will be adjusted as a result of the reverse split, as required by their terms.
• The number of shares reserved for future issuance pursuant to the 2015 Employee Stock Purchase Plan will also be appropriately adjusted.
• The reverse stock split will affect all stockholders uniformly and will not affect any stockholder's ownership percentage of shares, except to the extent that it results in cash in lieu of fractional shares.
• Stockholders will receive cash in lieu of fractional shares based on the closing price per share of common stock as quoted on the Nasdaq Capital Market on August 15, 2025.
• The reverse stock split will not reduce the number of authorized shares of common stock or preferred stock, nor change the par values of common stock or preferred stock, which will remain at $0.0001 per share.
• Equiniti Trust Company, LLC is acting as the exchange agent and transfer agent for the reverse stock split.

Sentiment

Score: 3

Explanation: The reverse stock split is a necessary action to maintain Nasdaq listing compliance due to a low stock price, which is generally viewed negatively by the market. While it addresses a technical requirement, it does not inherently improve the company's underlying business fundamentals or financial health. The significant reduction in outstanding shares reflects prior market underperformance.

Positives

• Aims to regain compliance with Nasdaq's $1.00 minimum bid price requirement, preventing potential delisting.
• Maintains the company's listing on the Nasdaq Capital Market, which is crucial for liquidity and investor confidence.
• The action was approved by stockholders and the Board of Directors, indicating internal alignment on the strategy to maintain listing.

Negatives

• Reverse stock splits are often perceived negatively by the market, signaling a low stock price and potential underlying financial or operational challenges.
• The significant reduction in outstanding shares (from approximately 7.6 million to approximately 509,000) reflects a substantial loss in per-share value prior to the split.
• Stockholders who would otherwise be entitled to fractional shares will receive cash, which may not be preferred by all investors.

Risks

• The company may not actually achieve the plans, intentions, or expectations disclosed in the forward-looking statements.
• Actual results could differ materially from described or implied results due to various risks and uncertainties.
• General market conditions can impact the company's results.
• Other risks detailed in the company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q filed with the SEC.

Future Outlook

The company expects the reverse stock split to enable it to regain compliance with the Nasdaq Capital Market's $1.00 minimum closing bid price requirement, ensuring continued listing. The company also notes that all outstanding options, warrants, and shares reserved for the 2015 Employee Stock Purchase Plan will be appropriately adjusted.

Management Comments

• Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that it will effect a 1-for-15 reverse stock split at 5:00 p.m. Eastern Time, on August 15, 2025.

Industry Context

Reverse stock splits are a common measure taken by companies, particularly those in the volatile biopharmaceutical sector, to maintain compliance with exchange listing requirements when their stock price falls below minimum thresholds. While necessary for continued listing, such actions often reflect underlying challenges in market valuation or operational performance, distinguishing them from companies with consistently strong stock performance.

Comparison to Industry Standards

• Many small-cap biopharmaceutical companies face similar challenges with stock price volatility and Nasdaq listing requirements, often resorting to reverse stock splits to avoid delisting.
• The 1-for-15 ratio is within the typical range for reverse splits aimed at achieving compliance, commonly observed in companies struggling to maintain a $1.00 minimum bid price.
• Unlike companies that achieve compliance through organic growth or significant positive clinical trial results, this action is a structural adjustment to meet a technical requirement, placing it in a category of companies facing market valuation pressures.

Corporate Governance

Stakeholder Impact

• Shareholders: The number of shares owned will decrease by a factor of 15, but ownership percentage (excluding fractional shares) will remain the same. Those with fractional shares will receive cash. The primary impact is the attempt to maintain Nasdaq listing, which benefits liquidity and market access.
• Employees: Shares reserved for the 2015 Employee Stock Purchase Plan will be adjusted, ensuring equity incentives remain proportional.
• Investors (General): The action aims to make the stock more attractive to institutional investors who may have policies against investing in 'penny stocks' and to maintain liquidity on Nasdaq.

Next Steps

• Trading on a split-adjusted basis under a new CUSIP number 79400X503 will begin on August 18, 2025.
• Equiniti Trust Company, LLC will provide instructions to stockholders with physical certificates for exchanging them for post-split shares and receiving cash for fractional shares.
• The company will continue to file reports with the SEC, including Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q.

Key Dates

Recommendation

The reverse stock split is a defensive maneuver to maintain Nasdaq listing, which is crucial for liquidity and investor access. While it addresses a technical compliance issue, it does not fundamentally alter the company's business prospects or financial performance. The underlying reasons for the low stock price (which necessitated the split) remain unaddressed in this filing. Investors should hold to observe if the company can leverage its continued listing to achieve clinical milestones or improve its financial standing, rather than selling based solely on a technical adjustment or buying without further fundamental analysis.

Keywords

Salarius Pharmaceuticals, SLRX, Reverse Stock Split, Nasdaq Compliance, Biopharmaceutical, Cancer Therapies, Stock Market, Corporate Action, SEC Filing, Clinical Stage